Compare Adaptive Biotechnologies Corp (ADPT) vs Dollar General Corp. (DG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Dollar General Corp. — how do they compare? Adaptive Biotechnologies Corp trades at $24.92 (market cap $4.04B), while Dollar General Corp. trades at $119.76 (market cap $26.49B). The key difference: Dollar General Corp. is far larger — about 6.6× Adaptive Biotechnologies Corp's market cap, and Dollar General Corp. pays a 1.97% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | DG | |
|---|---|---|
Market Cap | $4.04B | $26.49B |
Sector | Health | Consumer Staples |
52-Week High | $25.45 | $156.26 |
52-Week Low | $12.30 | $95.94 |
Enterprise Value | $4.10B | $40.93B |
Dividend Yield | — | 1.97% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $24.94, down 2.0% today but near its 52-week high. The stock shows a bullish technical trend with improving fundamentals, including 49% MRD revenue growth and narrowing losses. A recent 4:1 reverse stock split and planned business separation aim to unlock value, with analyst consensus leaning bullish.
Outlook is cautiously optimistic due to strong revenue growth and margin expansion, but risks persist from ongoing net losses and competitive pressures. The stock offers potential upside to the $25.50 consensus target if execution continues improving, yet volatility may remain until profitability is achieved.
Dollar General (DG) trades at $119.40, down 2.44% on the day, with a bullish technical signal despite recent weakness. The stock shows strong fundamentals with a P/E of 16.98 and P/S of 0.62, while consistently beating earnings expectations in recent quarters. Revenue growth continues with $40.61B in 2025, though profit margins have compressed from 7.01% in 2022 to 2.77% in 2025. Analyst consensus remains positive with 52% buy ratings and a $128.45 price target, representing 7.6% upside potential.
DG presents a compelling value opportunity with reasonable valuation metrics and consistent earnings beats, though margin compression and competitive pressures pose risks. The stock's current price near support levels combined with positive analyst sentiment suggests potential for recovery, but investors should monitor margin trends and competitive dynamics in the discount retail sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Dollar General Corp.
A leading American discount retailer, Dollar General operates over 18,000 stores in 47 states, selling branded and private-label products across a wide variety of categories. In fiscal 2021, 77% of net sales came from consumables (including paper and cleaning products, packaged and perishable food, tobacco, and health and beauty items), 12% from seasonal merchandise (such as toys, greeting cards, decorations, and gardening supplies), 7% from home products (for example, kitchen supplies, small appliances, and cookware), and 4% from basic apparel. Stores average roughly 7,400 square feet, and about 75% of Dollar General locations are in towns of 20,000 or fewer people. The firm emphasizes value, with most of its items sold at everyday low prices of $5 or less.
Read more on DG →
